Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology, will swallow Chicago-area biopharmaceutical developer NeoPharm Inc. (OTC:NEOL.PK) through a reverse merger worth an initial $135 million in stock.
The submission of the new drug application is "a major milestone" for NeoPharm, which posted operating losses of a combined $90 million in the three most recent years for which financial data was made public.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.